- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03706092
Impact of the Intervention of Pharmacists and Geriatrician on Drug Prescription in Elderly Patients in a Surgical ICU (IATROAGE)
Impact of the Intervention of Pharmacists and Geriatrician on Drug Prescription in Critically Ill Elderly Patients Admitted in Surgical ICU
In order to optimize drug prescription and to reduce potentially inappropriate medications, a pharmaceutical analysis activity is conducted in our establishment for several years. Medical prescriptions are reviewed daily by pharmacists. This activity is developed in approximatively 84% of the hospital wards of the institution, and especially in the geriatric department. Drug induced adverse effects are frequently encountered in elderly people and ICU environment causes a high risk of iatrogenic events because of the complexity of care and of the severity of illness. The hypothesis of the study is that the intervention of pharmacists and geriatricians could improve the medical prescription in elderly patients by reducing avoidable drug interactions and thus by decreasing the risk of drug induced adverse effects.
The primary objective of this study is to evaluate the impact of the intervention of pharmacists and geriatricians on medical prescription and on iatrogenic risk in elderly critically ill patients admitted in surgical ICU. The secondary objectives are (i) to describe the elderly patients population in surgical ICU, (ii) to analyze the impact of the ICU stay on medical prescription, (iii) to analyze the opportunities suggested by the pharmacists to optimize drug therapies and (iv) to assess the impact of drug prescription in the ICU on long-term disability.
A prospective, observational, before-after study will be conducted from august 1, 2018 to February 1, 2020, in the surgical ICU of the hospital. Patients older than 70 years and admitted to surgical ICU will be eligible. This study will be conducted in 2 successive steps: (1) first step: without any intervention of pharmacists or and geriatricians (Baseline), (2) second step: all drug prescription during the ICU and the hospital stay will be analyzed by a pharmacist and a geriatrician, to decrease drug interaction and risk of drug related adverse effect. During each step, the demographic and medical data will be recorded. Medical prescriptions will be reviewed at ICU admission, at 96 hours after ICU admission and then every 4 days until discharge from the ICU. For each patient, the impact of the intervention on mid-term and long-term disability will be assessed during a geriatric evaluation by using adequate specific scale at hospital discharge and at 3 months after hospital discharge. All iatrogenic events will be collected and analyzed.
Study Overview
Status
Conditions
Detailed Description
The aim of this study is to evaluate the impact of the intervention of pharmacists and geriatricians on medical prescription and on the iatrogenic risk in elderly critically ill patients admitted in surgical ICU. This study is before-after prospective study, carried out in 2 steps.
Step 1 data collection from August 1, 2018 to February 1, 2019
This step is a prospective analysis without any intervention of the pharmacist and of the geriatrician.
- The sociodemographic, and medical (comorbidities, reason for ICU admission, SAPS II (Simplified Acute Physiology Score) and SOFA (Sepsis-related Organ Failure Assessment) scores, laboratory data, invasive procedures data will be collected from ICU medical record.
- A geriatric evaluation and disability evaluation will be performed by using the ADL (Activity of Daily Living), Charlson, and SEGA (Short Emergency Geriatric Assessment) scales.
- The medical prescriptions will be reviewed at the first day and at 96 hours after admission in the ICU, and every 4 days during ICU stay. The pharmacist will analyse the medical prescriptions by using a standardized tool (Micromedex®, Theriaque®, Vidal®), to identify inappropriate prescription, and to assess the iatrogenic risks. These interventions will be quantified by using the SFPC Scale (French Society of clinical pharmacy).
- Iatrogenic events will be reported and analyzed.
- Drug prescription and patient outcome at discharge from the ICU and at discharge from the hospital will be collected.
- At 3 months from discharge from the hospital, a new geriatric evaluation will be conducted (patient's outcome and medical prescription).
Step 2, from March 1, 2019 to March, 2020.
This step is a prospective analysis with the intervention of the pharmacist and of the geriatrician.
The same data that step 1 will be collected. During this step, the pharmacist carries individualized interventions that will be discuss with the physician in charge of the patient to improve the safety of drug prescription. The physician will be allowed to accept or to refuse these interventions.
At 3 months from discharge from the hospital, a consultation with geriatrician will be proposed to the elderly patient. The geriatric evaluation and disability assessment will be conducted during this consultation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Besançon, France, 25000
- CHU de Besancon
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients 70 years or older
- admitted to surgical ICU
Exclusion Criteria:
- patients refusing data collection
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Before
Elderly patients > = 70 in ICU without any intervention of the pharmacists and of the geriatricians
|
After
Elderly patients > = 70 in ICU with individualized intervention of the pharmacists and of the geriatricians
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Impact of geriatric and pharmacist's intervention
Time Frame: Hospital stay until 3 months after
|
Difference between iatrogenic risks before/after pharmaceutical intervention on the elderly's prescription.
The iatrogenic risk is evaluated with the iatrogenic events rates and the inappropriate prescriptions rates.
|
Hospital stay until 3 months after
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Describe the medical characteristics of elderly patients population in surgical intensive care with the Charlson Comorbidities Index (CCI)
Time Frame: During hospital stay up to 3 months after discharge
|
Charlson Comorbidities Index Three grades of severity: mild, with CCI scores of 1-2; moderate, with CCI scores of 3-4; severe, with CCI scores ≥5 |
During hospital stay up to 3 months after discharge
|
Describe the medical characteristics of elderly patients population in surgical intensive care
Time Frame: During hospital stay up to 3 months after discharge
|
Rates of hospitalization's causes: surgical emergency causes, elective surgery causes, medical emergency causes, elective medical causes
|
During hospital stay up to 3 months after discharge
|
Describe the demographic elderly patients population in surgical intensive care
Time Frame: During hospital stay up to 3 months after discharge
|
age, sex
|
During hospital stay up to 3 months after discharge
|
Impact of a stay surgical intensive care on medical prescription change
Time Frame: During Hospital stay in ICU (Day 0, 4, 8, 12, 16) and 3 months after discharge
|
number of new treatment, number of new interaction, number of iatrogenic event, before/after surgical intensive care
|
During Hospital stay in ICU (Day 0, 4, 8, 12, 16) and 3 months after discharge
|
Evaluate the intervention's impact on the disability and geriatric evaluation with ADL scale
Time Frame: 3 months after hospital discharge
|
Evolution of disability and geriatric evaluation before/after intervention: - ADL (Activity Daily Living evolution of the different geriatrics scores) 0 : dependance, 6 autonomy |
3 months after hospital discharge
|
Evaluate the intervention's impact on the disability and geriatric evaluation with SEGA scale
Time Frame: 3 months after hospital discharge
|
Evolution of disability and geriatric evaluation before/after intervention: - SEGA (Short Emergency Geriatric Assessment): 0-26 < or = 8 : Low fragility, 9-11: fragility, > or = 12 Very fragile person |
3 months after hospital discharge
|
Analyse the opportunities suggested by the pharmacist for optimization of drug therapies
Time Frame: During Hospital stay ICU (Day 0, 4, 8, 12, 16)
|
rates of kind opportunities suggested by the pharmacist (dosage adjustment, galenic form change, inappropriate medication ...)
|
During Hospital stay ICU (Day 0, 4, 8, 12, 16)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anne Laure CLAIRET, CHU de Besancon
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- IATROAGE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Care
-
Potrero MedicalCompletedCritical Care, Intensive Care
-
Hospital Israelita Albert EinsteinActive, not recruitingCritical Care | Intensive Care UnitBrazil
-
University College, LondonCompleted
-
Hospital do CoracaoD'Or Institute for Research and Education; Sociedade Hospital SamaritanoCompleted
-
Hospital Nossa Senhora da ConceicaoRecruiting
-
Hospices Civils de LyonRecruiting
-
University Hospital, ToursCompleted
-
Hospitech RespirationCompleted
-
Centre Hospitalier Universitaire de BesanconCompleted
-
InLight SolutionsLuminous MedicalCompletedCritical CareUnited States